Ventana Medical Systems, Inc., is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide. The company passionately pursues its mission to improve the lives of all patients afflicted with cancer. Ventana Medical Systems discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 220 cancer tests with related instruments right here in southern Arizona for 80 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety. Ventana is committed to accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient samples at the molecular level to help determine the best course of therapy for each individual patient. Ventana enables this with its global leadership as the number one Pharma Industry Partner of Choice in the development and commercialization of companion diagnostics for cancer patients. Ventana Medical Systems is a member of the Roche Group that is drawing on powerful partnerships with world-class scientific institutions.

Part of Medtronic Plc, Covidien Pte Ltd. is a Singaporean company located in Singapore that manufactures and supplies medical equipment.

Konica Minolta Inc. is an Innovative Company and continues to create inspiring products and services in the field of imaging. An innovative corporation that continues to create inspiring products and services in the field of imaging. A global corporation that leads the market by advanced technologies and reliability. The Konica Minolta brand shows intellectual creativity with its challenging, reliable, friendly personality. Four unique characteristics help realize the ideal value of the brand: broad technical expertise covering the entire imaging field; a culture relentlessly committed to creating great products and services; unique product groups developed from integrated technologies; a marketing service network that swiftly copes with customers’ needs. The essence of their brand is Konica Minolta’s comprehensive technological expertise that yields highly original innovations, which are a constant source of surprise to customers. The logo is a representation of their brand value and company name and expresses what Konica Minolta offers to customers. The Konica Minolta Group owns a wide array of specialized technologies and technologies that support the competitiveness and attractiveness of their products. These technologies are defined as our core technologies, totaling twelve – four in materials, two in optics, two in nano-fabrication and four in imaging fields. Throughout their history, they have expanded and advanced these technologies, integrating them at whole new levels so that they are the driving force of our production activities. They continuously strive to integrate these technologies into innovative products with new functions and added value that contribute to the daily lives of people at home and at work. Naturally, this also includes our range of Business Solution products.

Neurogen Corporation is a drug development company historically focusing on small-molecule drugs to improve the lives of patients suffering from psychiatric and neurological disorders with significant unmet medical need. Neurogen has conducted its drug development independently and, when advantageous, collaborated with world-class pharmaceutical companies to access additional resources and expertise.

Clarapath is a medical robotics company automating the laboratory. The company's first product is focused on fully automating the microtomy station in pathology. Their vision is to innovate, standardize, and digitally transform anatomic pathology through higher-quality lab medicine, more robust safety standards, and increased lab throughput while lowering laboratory costs and labor-related delays. Their next-generation laboratory at the NY Genome Center together with our large-scale image repository and analysis platform are designed to handle the entire “tissue to bits” pipeline for special research projects as well as larger-scale clinical needs. Clarapath works closely with both research and clinical customers to produce faster, more accurate results.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Boston Scientific Scimed, Inc. develops, manufactures, and markets medical devices used principally to treat cardiovascular disease.

Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO.

United States Surgical Corporation manufactures and markets wound closure products and advanced surgical devices. The company’s divisions include the Auto Suture, which offers surgical devices and laparoscopic instrumentation for general and specialty procedures; the Syneture Division that provides sutures and biosurgery products; and USS Sports Medicine, that offers spinal fixation and sports medicine products.

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Part of Bruker Corp., Bruker Daltonik GmbH is a German company located in Bremen. The firm manufactures mass spectrometry systems for life sciences. Jürgen Srega, Wolfgang Pusch and Rohan Ashok Thakur are the current co-CEOs of the company.

Leica Biosystems Nussloch GmbH, a subsidiary of Danaher Corp., is a company headquartered in Nussloch, Germany. The firm operates as cancer diagnostics company for tackling pathology challenges.\nThe company says this about itself: Leica Biosystems is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of \"Advancing Cancer Diagnostics, Improving Lives\" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

HistoRx is developing theranostic solutions to towards individualized patient care. HistoRx's proprietary technology delivers objective and reproducible multiparametric analysis of proteins in tissue, providing insights into cancer treatment.

Guizhou Golden Mile Medical Testing Center Co., Ltd., established on 2010-01-18, Business scope includes legal,regulations,Those prohibited by the State Council's decision shall not operate;law,regulations,The State Council has decided to allow(approval)of,After approval by the examination and approval authority(approval)file management;law,regulations,The State Council has decided that a license is not required(approval)of,Market entities independently choose to operate.(Clinical Chemistry,Clinical immunization room,Clinical Microbiology Room,clinical blood,body fluid compartment,Molecular Biology Laboratory,Pathology laboratory,Clinical Cytomolecular Genetics Major;Sales:medical instruments.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments.))

BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

LSI Solutions, Inc. is an American private company. The firm manufactures and markets invasive surgical instruments.

TissUse is a Berlin, Germany-based, vibrant growth company who has developed a unique "Multi-Organ-Chip" platform that - for the first time ever - provides preclinical insight on the systemic level using human tissue. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse's Multi-Organ-Chips provide a completely new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.